Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.

被引：0
|
作者：
Saliby, Renee Maria
Xie, Wanling
Wells, J. Connor
Saad, Eddy
Eid, Marc
Labaki, Chris
Semaan, Karl
Ferrier, Evan
Lemelin, Audreylie
Suarez, Cristina
Ruiz-Morales, Jose Manuel
Powles, Thomas
Wood, Lori
Ebrahimi, Hedyeh
de Velasco, Guillermo
Takemura, Kosuke null
Agarwal, Neeraj
Braun, David A.
Heng, Daniel Yick Chin
Choueiri, Toni K.
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Dana Farber Canc Inst, Dept Data Sci, Boston, MA USA
[3] BC Canc Agcy, Calgary, AB, Canada
[4] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[5] Tom Baker Canc Clin, Calgary, AB, Canada
[6] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[7] Med Sur SAB CV, Toriello Guerra, DF, Mexico
[8] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, London, England
[9] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada
[10] City Hope Comprehens Canc Ctr, Duarte, CA USA
[11] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[12] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[13] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[14] Yale Univ, New Haven, CT USA
[15] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[16] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02215 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-492-3532-2370-7650-2700; 283-2494-9200; 261-566-9718-9794; 613-4678-146-485; 613-135-2370-7646-2344; 261-566-9690; 6; 2; 1808; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.400
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：400 / 400
页数：1
相关论文
共 50 条
  • [1] Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study
    Saliby, Renee Maria
    Xie, Wanling
    Wells, Connor J.
    Saad, Eddy
    Eid, Marc
    Semaan, Karl
    Labaki, Chris
    Ferrier, Evan
    Zarba, Martin
    Ebrahimi, Hedyeh
    Ravi, Praful
    Suarez, Cristina
    Morales, Jose Ruiz
    Mckay, Rana R.
    Powles, Thomas
    Wood, Lori
    Lalani, Aly-Khan A.
    Pal, Sumanta K.
    de Velasco, Guillermo
    Takemura, Kosuke
    Agarwal, Neeraj
    Braun, David A.
    Heng, Daniel Y.
    Choueiri, Toni K.
    ONCOLOGIST, 2024, 29
  • [2] Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
    Saliby, R. M.
    Xie, W.
    Wells, J. C.
    Saad, E.
    Eid, M.
    Semaan, K.
    Labaki, C.
    Ferrier, E.
    Zarba, M.
    Ebrahimi, H.
    Suarez Rodriguez, C.
    Ruiz, J. M.
    Powles, T. B.
    Wood, L. A.
    De Velasco Oria, G. A.
    Takemura, K.
    Braun, D. A.
    Heng, D. Y. C.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1021 - S1022
  • [3] Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC)-an International mRCC Database Consortium (IMDC) analysis
    Araujo, Daniel, V
    Wells, J. Connor
    Hansen, Aaron R.
    Dizman, Nazli
    Pal, Sumanta K.
    Beuselinck, Benoit
    Donskov, Frede
    Gan, Chun L.
    Yan, Flora
    Tran, Ben
    Kollmannsberger, Christian K.
    de Velasco, Guillermo
    Yuasa, Takeshi
    Reaume, M. Neil
    Ernst, D. Scott
    Powles, Thomas
    Bjarnason, Georg A.
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    Dudani, Shaan
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 820 - 826
  • [4] Impact of cytoreductive nephrectomy (CN) on survival in metastatic renal cell cancer (mRCC) treated with immune checkpoint inhibitors (ICI).
    Perimbeti, Stuthi
    Jiang, Changchuan
    Deng, Lei
    Roy, Arya
    Gopalakrishnan, Keerthy
    Chatta, Gurkamal S.
    George, Saby
    Gopalakrishnan, Dharmesh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [5] Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis.
    Araujo, Daniel Vilarim
    Wells, Connor
    Hansen, Aaron Richard
    Dizman, Nazli
    Pal, Sumanta K.
    Beuselinck, Benoit
    Donskov, Frede
    Gan, Chun Loo
    Yan, Flora
    Tran, Ben
    Kollmannsberger, Christian K.
    de Velasco, Guillermo
    Yuasa, Takeshi
    Reaume, M. Neil
    Ernst, D. Scott
    Powles, Thomas
    Bjarnason, Georg A.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    Dudani, Shaan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] A real-world experience of immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC)
    Elias, Roy
    Levonyak, Nicholas
    Christie, Alana
    Bowman, Isaac Alexander
    Kapur, Payal
    Hannan, Raquibul
    Hammers, Hans J.
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] Efficacy of immune checkpoint inhibitors (ICI) treatment in special populations of metastatic renal cell carcinoma (mRCC)
    Araujo, Daniel Vilarim
    Malone, Eoghan Ruadh
    Sacher, Adrian G.
    Fallah-Rad, Nazanin
    Sridhar, Srikala S.
    Hansen, Aaron Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
    Martini, Dylan J.
    Liu, Yuan
    Shabto, Julie M.
    Carthon, Bradley Curtis
    Russler, Greta
    Hitron, Elise
    Caulfield, Sarah
    Kissick, Haydn
    Harris, Wayne
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Baseline modified Glasgow prognostic score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI).
    Brown, Jacqueline T.
    Liu, Yuan
    Martini, Dylan J.
    Shabto, Julie M.
    Russler, Greta
    Caulfield, Sarah
    Yantorni, Lauren Beth
    Joshi, Shreyas S.
    Kissick, Haydn
    Ogan, Kenneth
    Nazha, Bassel
    Carthon, Bradley Curtis
    Kucuk, Omer
    Harris, Wayne
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Impact of renin-angiotensin system inhibitors (RASi) on outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI)
    Nuzzo, P. V.
    Adib, E.
    Weise, N.
    Curran, C.
    Stewart, T.
    Freeman, D.
    Nassar, A. H.
    Abou Alaiwi, S.
    Bakouny, Z.
    McGregor, B. A.
    Choueiri, T. K.
    Jain, R. K.
    Mckay, R. R.
    Sonpavde, G. P.
    ANNALS OF ONCOLOGY, 2021, 32 : S702 - S703
12345